Label: DEXAMETHASONE- dexamethasone elixir

  • NDC Code(s): 64980-509-24
  • Packager: Rising Pharmaceuticals, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated December 3, 2017

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Each 5 mL (teaspoonful) contains:
    Dexamethasone, USP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.5 mg

    Also contains:
    Benzoic Acid, USP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.1%
      (as preservative)
    Alcohol (% v/v) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.1%

    Inactive Ingredients: artificial raspberry flavor; citric acid; FD&C red no. 40; sucrose; propylene glycol and purified water. It may also contain sodium citrate dihydrate.

    Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract.

    Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water. The molecular weight is 392.47. It is designated chemically as 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione. The molecular formula is C22H29FO5 and the structural formula is:

    structure

    Close
  • CLINICAL PHARMACOLOGY

    Naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, including dexamethasone, are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.

    Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.

    At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone.

    Close
  • INDICATIONS AND USAGE

    1. Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
      Congenital adrenal hyperplasia
      Nonsuppurative thyroiditis
      Hypercalcemia associated with cancer
    2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
      Psoriatic arthritis
      Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
      Ankylosing spondylitis
      Acute and subacute bursitis
      Acute nonspecific tenosynovitis
      Acute gouty arthritis
      Post-traumatic osteoarthritis
      Synovitis of osteoarthritis
      Epicondylitis
    3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of:
      Systemic lupus erythematosus
      Acute rheumatic carditis
    4. Dermatologic Diseases:
      Pemphigus
      Bullous dermatitis herpetiformis
      Severe erythema multiforme (Stevens-Johnson syndrome)
      Exfoliative dermatitis
      Mycosis fungoides
      Severe psoriasis
      Severe seborrheic dermatitis
    5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
      Seasonal or perennial allergic rhinitis
      Bronchial asthma
      Contact dermatitis
      Atopic dermatitis
      Serum sickness
      Drug hypersensitivity reactions
    6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as:
      Allergic conjunctivitis
      Keratitis
      Allergic corneal marginal ulcers
      Herpes zoster ophthalmicus
      Iritis and iridocyclitis
      Chorioretinitis
      Anterior segment inflammation
      Diffuse posterior uveitis and choroiditis
      Optic neuritis
      Sympathetic ophthalmia
    7. Respiratory Diseases:
      Symptomatic sarcoidosis
      Loeffler's syndrome not manageable by other means
      Berylliosis
      Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
      Aspiration pneumonitis
    8. Hematologic Disorders:
      Idiopathic thrombocytopenic purpura in adults
      Secondary thrombocytopenia in adults
      Acquired (autoimmune) hemolytic anemia
      Erythroblastopenia (RBC anemia)
      Congenital (erythroid) hypoplastic anemia
    9. Neoplastic Diseases: For palliative management of:
      Leukemia and lymphomas in adults
      Acute leukemia of childhood
    10. Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus
    11. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in:
      Ulcerative colitis
      Regional enteritis
    12. Miscellaneous:
      Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
      Trichinosis with neurologic or myocardial involvement
    13. Diagnostic testing of adrenocortical hyperfunction.
    Close
  • WARNINGS

    In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

    Drug-induced secondary adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving steroids already, dosage may have to be increased. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

    Corticosteroids may mask some signs of infection, and new infections may appear during their use. There may be decreased resistance and inability to localize infection when corticosteroids are used. Moreover, corticosteroids may affect the nitroblue-tetrazolium test for bacterial infection and produce false-negative results.

    In cerebral malaria, a double-blind trial has shown that the use of corticosteroids is associated with prolongation of coma and a higher incidence of pneumonia and gastrointestinal bleeding.

    Corticosteroids may activate latent amebiasis. Therefore, it is recommended that latent or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained diarrhea.

    Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.

    Close
  • PREGNANCY

    Usage in Pregnancy: Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.

    Corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. Mothers taking pharmacologic doses of corticosteroids should be advised not to nurse.

    Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

    Administration of live virus vaccines, including smallpox, is contraindicated in individuals receiving immunosuppressive doses of corticosteroids. If inactivated viral or bacterial vaccines are administered to individuals receiving immunosuppressive doses of corticosteroids, the expected serum antibody response may not be obtained. However, immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease.

    Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chickenpox develops, treatment with antiviral agents may be considered.

    The use of Dexamethasone Elixir in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.

    If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

    Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients.

    Close
  • PRECAUTIONS

    Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the corticosteroid withdrawal syndrome including fever, myalgia, arthralgia, and malaise. This may occur in patients even without evidence of adrenal insufficiency.

    There is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis.

    Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

    The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

    Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

    Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

    Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess, or other pyogenic infection, diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis and myasthenia gravis. Signs of peritoneal irritation following gastrointestinal perforation in patients receiving large doses of corticosteroids may be minimal or absent. Fat embolism has been reported as a possible complication of hypercortisonism.

    When large doses are given, some authorities advise that corticosteroids be taken with meals and antacids taken between meals to help to prevent peptic ulcer.

    Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

    Steroids may increase or decrease motility and number of spermatozoa in some patients.

    Phenytoin, phenobarbital, ephedrine, and rifampin may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring adjustment in corticosteroid dosage. These interactions may interfere with dexamethasone suppression tests which should be interpreted with caution during administration of these drugs.

    False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients.

    The prothrombin time should be checked frequently in patients who are receiving corticosteroids and coumarin anticoagulants at the same time because of reports that corticosteroids have altered the response to these anticoagulants. Studies have shown that the usual effect produced by adding corticosteroids is inhibition of response to coumarins, although there have been some conflicting reports of potentiation not substantiated by studies.

    When corticosteroids are administered concomitantly with potassium-depleting diuretics, patients should be observed closely for development of hypokalemia.

    Close
  • Information for Patients:

    Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.

    Close
  • ADVERSE REACTIONS

    Fluid and Electrolyte Disturbances:

    Sodium retention
    Fluid retention
    Congestive heart failure in susceptible patients
    Potassium loss
    Hypokalemic alkalosis
    Hypertension
    Musculoskeletal:

    Muscle weakness
    Steroid myopathy
    Osteoporosis
    Aseptic necrosis of femoral and humeral heads
    Vertebral compression fractures
    Loss of muscle mass
    Pathologic fracture of long bones
    Tendon rupture
    Gastrointestinal:

    Pancreatitis
    Abdominal distention
    Peptic ulcer with possible perforation and hemorrhage
    Ulcerative esophagitis
    Perforation of the small and large bowel, particularly in patients with inflammatory bowel disease
    Dermatologic:

    Impaired wound healing
    Thin fragile skin
    Erythema
    May suppress reactions to skin tests
    Petechiae and ecchymoses
    Increased sweating
    Other cutaneous reactions, such as allergic dermatitis, urticaria, angioneurotic edema
    Neurologic:

    Convulsions
    Vertigo
    Headache
    Psychic Disturbances
    Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment
    Endocrine:

    Menstrual irregularities
    Development of cushingoid state
    Manifestations of latent diabetes mellitus
    Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness
    Decreased carbohydrate tolerance
    Suppression of growth in children
    Increased requirements for insulin or oral hypoglycemic agents in diabetes
    Hirsutism
    Ophthalmic:

    Posterior subcapsular cataracts
    Increased intraocular pressure
    Glaucoma
    Exophthalmos

    Metabolic:

    Negative nitrogen balance due to protein catabolism
    Cardiovascular:

    Myocardial rupture following recent myocardial infarction (See WARNINGS)
    Other:

    Hypersensitivity
    Thromboembolism
    Weight gain
    Increased appetite
    Nausea
    Malaise
    Hiccups
    Close
  • SPL UNCLASSIFIED SECTION

    To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharmaceuticals, Inc. at 1-866-562-4597 or FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch

    Close
  • OVERDOSAGE

    Reports of acute toxicity and/or death following overdosage of glucocorticoids are rare. In the event of overdosage, no specific antidote is available; treatment is supportive and symptomatic.

    The oral LD50 of dexamethasone in female mice was 6.5 g/kg.

    Close
  • HOW SUPPLIED

    Dexamethasone Elixir, USP 0.5 mg/5 mL is supplied as a clear, red, raspberry-flavored liquid in the following size:
       8 fl oz (237 mL) bottle

    RECOMMENDED STORAGE

    Store at 20˚-25˚C (68˚-77˚F) [See USP Controlled Room Temperature].

    KEEP TIGHTLY CLOSED

    AVOID FREEZING

    Dispense in a tight container as defined in the USP.

    Rx Only

    Manufactured for:

    Rising Pharmaceuticals, Inc.
    Allendale, NJ 07401

    Manufactured by:

    Lyne Laboratories, Inc.
    Brockton, MA 02301

    R6-10/16

    Close
  • PRINCIPAL DISPLAY PANEL

    Rising®       NDC 64980-509-24

    Dexamethasone
    Elixir, USP

    0.5 mg/5 mL

    Contains 5.1% Alcohol (% v/v)

    NET: 8 fl oz (237 mL)       Rx only

    label

    Close
  • INGREDIENTS AND APPEARANCE
    DEXAMETHASONE 
    dexamethasone elixir
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:64980-509
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Dexamethasone (UNII: 7S5I7G3JQL) (Dexamethasone - UNII:7S5I7G3JQL) Dexamethasone 0.5 mg  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    BENZOIC ACID (UNII: 8SKN0B0MIM)  
    ALCOHOL (UNII: 3K9958V90M)  
    ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    SUCROSE (UNII: C151H8M554)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    WATER (UNII: 059QF0KO0R)  
    TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)  
    Product Characteristics
    Color red (clear) Score     
    Shape Size
    Flavor RASPBERRY (artificial raspberry flavor) Imprint Code
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:64980-509-24 237 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 08/01/2011
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA090891 08/01/2011
    Labeler - Rising Pharmaceuticals, Inc. (041241766)
    Registrant - Lyne Laboratories, Inc. (053510459)
    Establishment
    Name Address ID/FEI Business Operations
    Lyne Laboratories, Inc. 053510459 manufacture(64980-509)
    Close